Cargando…

Novel technologies in cfDNA analysis and potential utility in clinic

The profiling of plasma cell-free DNA (cfDNA) is becoming a valuable tool rapidly for tumor diagnosis, monitoring and prognosis. Diverse plasma cfDNA technologies have been in routine or emerging use, including analyses of mutations, copy number alterations, gene fusions and DNA methylation. Recentl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jie, Xu, Mengyue, Peng, Junya, Wang, Jingqiao, Zhao, Yupei, Wu, Wenming, Lan, Xun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742177/ https://www.ncbi.nlm.nih.gov/pubmed/35125814 http://dx.doi.org/10.21147/j.issn.1000-9604.2021.06.07

Ejemplares similares

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis
por: Jackson Chornenki, Nicholas L., et al.
Publicado: (2019)

The utility of cfDNA in TGCT patient management: a systematic review
por: Krasic, Jure, et al.
Publicado: (2022)

Erratum to “The utility of cfDNA in TGCT patient management: a systematic review”
Publicado: (2022)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer
por: Wu, Zhiwei, et al.
Publicado: (2022)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker
por: Škara, Lucija, et al.
Publicado: (2023)

In silico error correction improves cfDNA mutation calling
por: Kim, Chang Sik, et al.
Publicado: (2019)

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
por: Gerard, Laura, et al.
Publicado: (2021)

Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer
por: Liang, Leilei, et al.
Publicado: (2022)

Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity
por: Ivanov, Maxim, et al.
Publicado: (2019)

Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer
por: Zhong, Yuejiao, et al.
Publicado: (2020)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
por: Togneri, Fiona S, et al.
Publicado: (2016)

cfDNA screening and diagnosis of monogenic disorders – where are we heading?
por: Chiu, Eunice Ka Long, et al.
Publicado: (2018)

Detection of LINE-1 hypomethylation in cfDNA of Esophageal Adenocarcinoma Patients
por: Boldrin, Elisa, et al.
Publicado: (2020)

Impact of mosaicism ratio on positive predictive value of cfDNA screening
por: Rafalko, Jill M., et al.
Publicado: (2020)

cfDNA Changes in Maximal Exercises as a Sport Adaptation Predictor
por: Humińska-Lisowska, Kinga, et al.
Publicado: (2021)

Deep cfDNA fragment end profiling enables cancer detection
por: Zhitnyuk, Yulia V., et al.
Publicado: (2022)

Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants
por: Sugasawa, Takehito, et al.
Publicado: (2021)

cfDNA Methylation Profiles and T-Cell Differentiation in Women with Endometrial Polyps
por: Li, Xiao-Hong, et al.
Publicado: (2022)

Hypertensive disorders of pregnancy share common cfDNA methylation profiles
por: Spinelli, Marialuigia, et al.
Publicado: (2022)

Brave new world of cfDNA-omics for early cancer detection
por: Rolfo, Christian, et al.
Publicado: (2023)

cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
por: He, Qiong, et al.
Publicado: (2020)

A DNA-modified hydrogel for simultaneous purification, concentration and detection of targeted cfDNA in human serum
por: Jiang, Xinglu, et al.
Publicado: (2019)

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
por: García-Pardo, Miguel, et al.
Publicado: (2022)

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
por: Dao, Jonathan, et al.
Publicado: (2023)

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing
por: Medina Diaz, Inga, et al.
Publicado: (2016)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors
por: McEwen, Abbye E., et al.
Publicado: (2020)

Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer
por: Silva, Romina, et al.
Publicado: (2021)

MSIsensor-ct: microsatellite instability detection using cfDNA sequencing data
por: Han, Xinyin, et al.
Publicado: (2021)

Evaluation of cfDNA as an early detection assay for dense tissue breast cancer
por: Barbirou, Mouadh, et al.
Publicado: (2022)

cfDNA methylome profiling for detection and subtyping of small cell lung cancers
por: Chemi, Francesca, et al.
Publicado: (2022)

Altered cfDNA fragmentation profile in hypomethylated regions as diagnostic markers in breast cancer
por: Wang, Jun, et al.
Publicado: (2023)

The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
por: Zhao, Xiaolong, et al.
Publicado: (2021)

Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer
por: Thakur, Kavita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nj5t33i3lke37a1aqavc6v40im